TYRA
Tyra Biosciences, Inc.Healthcare · $1.3B market cap
Verdict
We can't put a fair value on TYRA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow TYRA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 9, 2026: 1 open-market purchase worth $20K. Why purchases matter
Purchases
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works